Cyclophosphamide Systemic Sclerosis Associated Interstitial Lung Disease

Exclusion Criteria

• •Prednisone prescribed a dose greater than 15 mg/d during the last 3 months.
• •Scleroderma renal crisis or acute or critical limb ischemia within the last year preceding inclusion,
• •Left ventricular ejection fraction below 40% evaluated by echocardiography.
• •Out of proportion pulmonary hypertension (mean pulmonary artery pressure above 35 mmHg upon right heart catheterization).
• •CYC treatment during the last 12 months.
• •Allergy, hypersensitivity or documented adverse events or contra-indications to the drugs used in the study (cyclophosphamide, Uromitexan, corticosteroids, domperidone ...)
• •Patients with a past history of cancer within four years before inclusion and/or a history of chemotherapy for cancer within four years before inclusion (in remission or without disease activity for more than four years). Inclusion is authorized for patients with a basal cell carcinoma in the last 5 years.
• •Severe infection: sepsis, cellulitis, gangrene in the last three months
• •Past history of cystitis related to cyclophosphamide treatment
• •Association to another connective disease : systemic lupus erythematosus, syndrome of Gougerot-Sjögren with anti-SSA/SSB, mixed connective tissue disease
• •Patient breastfeeding
• •Failure to sign the informed consent or unable to consent
• •Patient participating in another clinical trial
• •Injection of Rituximab within 6 months preceding inclusion
• •Methotrexate or Cellcept treatment at inclusion